

# PRODUCT INFORMATION




## RIG-I Monoclonal Antibody (Clone 1E3)

Item No. 25300


### Overview and Properties

<b>Contents:</b>	This vial contains 100 µg of protein G-purified antibody.
<b>Synonyms:</b>	Probable ATP-dependent RNA Helicase DDX58, DEAD Box Protein 58, Retinoic Acid-inducible Gene 1 Protein, RIG-I-like Receptor 1
<b>Immunogen:</b>	Recombinant human RIG-I protein AA 232-794
<b>Species Reactivity:</b>	(+) Human, mouse; other species not tested
<b>Uniprot No.:</b>	O95786
<b>Form:</b>	Liquid
<b>Storage:</b>	-20°C (as supplied)
<b>Stability:</b>	≥3 years
<b>Storage Buffer:</b>	PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
<b>Clone:</b>	1E3
<b>Host:</b>	Mouse
<b>Isotype:</b>	IgG2b
<b>Applications:</b>	ELISA, Western blot (WB), and immunohistochemistry (IHC); the recommended starting dilution for ELISA and WB is 1:1,000 and 1:200 for IHC. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

### Images



Lane 1: RIG-I (human recombinant) (AA 232-794) (5 ng)  
Lane 2: RIG-I (human recombinant) (AA 232-794) (10 ng)  
Lane 3: Jurkat cell lysate (50 µg)  
Lane 4: MCF-7 cell lysate (50 µg)



Immunohistochemistry analysis of formalin-fixed, paraffin-embedded (FFPE) human kidney tissue after heat-induced antigen retrieval in pH 6.0 citrate buffer. After incubation with RIG-I monoclonal antibody (clone 1E3) (Item No. 25300) at a 1:200 dilution, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphate-streptavidin and chromogen (DAB).

WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/04/2023

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

Retinoic acid-inducible gene I (RIG-I), also known as DDX58, is a cytosolic DExD/H-box RNA helicase and an immune sensing receptor encoded by *DDX58* in humans.<sup>1</sup> It is composed of a C-terminal repressor domain, a central RNA helicase domain, and two N-terminal caspase recruitment domains (CARDs).<sup>1,2</sup> Following recognition of viral dsRNA by the C-terminal and helicase domains, the helicase domain induces an ATP-dependent conformational change, allowing for interaction of the CARD domains with mitochondrial antiviral-signaling protein (MAVS) and induction of a type I interferon (IFN) response.<sup>1-3</sup> RIG-I levels are elevated in the epidermis of patients with psoriasis.<sup>2</sup> *DDX58* expression is decreased in tumor tissues from patients with hepatocellular carcinoma (HCC) compared to nontumor hepatic tissue, and low *DDX58* expression is associated with poor disease prognosis.<sup>4</sup> Cayman's RIG-I Monoclonal Antibody (Clone 1E3) can be used for Western blot, ELISA, and immunohistochemistry applications. The antibody recognizes RIG-I at 106.6 kDa from human and mouse samples.

## References

---

1. Hartmann, G. Nucleic acid immunity. *Adv. Immunol.* **133**, 121-169 (2017).
2. Matsumiya, T. and Stafforini, D.M. Function and regulation of retinoic acid-inducible gene-I. *Crit. Rev. Immunol.* **30(6)**, 489-513 (2010).
3. Takeuchi, O. and Akira, S. Innate immunity to virus infection. *Immunol. Rev.* **277(1)**, 75-86 (2009).
4. Hou, J., Zhou, Y., Zheng, Y., *et al.* Hepatic RIG-I predicts survival and interferon- $\alpha$  therapeutic response in hepatocellular carcinoma. *Cancer Cell.* **25(1)**, 49-63 (2014).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM